logo-loader
Avacta Group PLC

Avacta Group - Capital Network: Preliminary Results

Avacta’s FY 2017 Preliminary Results: Reagents and therapeutics programs all on track

KEY INVESTOR MESSAGES

  • Avacta’s Affimer® technology is a proprietary alternative to antibodies with key technical and commercial benefits
  • Avacta is building a pipeline of Affimer drugs for immuno-oncology and growing revenues based on a licensing model for Affimer reagents
  • Excellent progress in both parts of the business during the reporting period substantially de-risking the opportunity
  • A pipeline of potential valuable and licensable drugs is being built and the company is targeting first clinical trials in 2019
  • A sum-of-the-parts model now suggests an equity value four times the current market capitalisation

 

RESULTS SUMMARY

On the 4th October, Avacta Group Plc (LON:AVCT) has reported preliminary results for the fiscal year ending July 2017, including a detailed update on the business.

Overall Avacta Group Plc (LON:AVCT) is delivering according to management's guidance and has made significant progress in both the Affimer reagents' business and the Affimer therapeutics programs (please refer to our initiation report of March 2017 for an overview of Avacta's Affimer technology and business strategy).

As regards the Reagents business, Avacta Group Plc (LON:AVCT) announced in April 2017 that, after a trial period, they have granted a leading diagnostic company exclusive rights to specific Affimer reagents. Although financial details weren't disclosed, this was the first time that Avacta signed an agreement of this nature, representing an important inflection point in de-risking the reagents business.

As such we remove any risk adjustment from our valuation of the Affimer reagents business, which we now value approx. £140mil, from about £110mil before this deal was signed.

Executive summary

NEXT STEPS

Following the release of FY 2017 preliminary results, we have updated our chart showing the key upcoming milestones for Avacta's reagents and therapeutic programs.
 
Affimer Therapeutics
 
As regards the further pre-clinical development of the Affimer's immuno-oncology program, we expect Avacta to focus on additional in-vivo PK and toxicity studies and on the preparation of the tech transfer and CMC (chemistry, manufacturing and control) dossier.
 
We also note that Avacta's collaborations with Moderna, the Sloan Kettering Cancer Center and Glythera are all progressing according to plan and are due updates over the next 12 months.

Affimer reagents
 
With custom Affimers' order book up 91% y-o-y, we would expect that one or more of the ongoing paid-for evaluations will lead to the finalization of further licensing agreements in the coming quarters.

 

Quick facts: Avacta Group PLC

Price: £0.22

Market: AIM
Market Cap: £26.02 m
Follow

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Watch

Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

4 min read